CCCC Stock Gets Pre-Market Boost On Roche Tie-Up To Develop Cancer Treatments

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.
Representative image of a stock chart
Representative image of a stock chart. (Photo: Getty Images)
Profile Image
Arnab Paul·Stocktwits
Published Apr 09, 2026   |   8:08 AM EDT
Share
·
Add us onAdd us on Google

Shares of C4 Therapeutics, Inc. (CCCC) jumped 5% higher in pre-market trading on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.

C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes. As part of the agreement, C4 Therapeutics and Roche will work together on two programs to develop DAC therapies targeting undisclosed cancer indications.

C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments, along with tiered royalties on future sales. 

Get updates to this story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Follow on Google News
Read about our editorial guidelines and ethics policy